Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms.

In English

Författare

  • Åsa Tivesten
  • Jehonathan H Pinthus
  • Noel Clarke
  • Wilhelmina Duivenvoorden
  • Jan Nilsson

Summary, in English

Androgen deprivation therapy (ADT) is frequently used for the treatment of advanced prostate cancer. ADT is associated with numerous side effects related to its mode of action, namely the suppression of testosterone to castrate levels. Recently, several large retrospective studies have also reported an increased risk of diabetes and cardiovascular disease in men receiving ADT, although these risks have not been confirmed by prospective randomized trials. We review the literature to consider the risk of cardiovascular disease with different forms of ADT and examine in detail potential mechanisms by which any such risk could be mediated. Mechanisms discussed include the metabolic syndrome resulting from low testosterone level and the potential roles of testosterone flare, gonadotropin-releasing hormone receptors outside the pituitary gland, and altered levels of follicle-stimulating hormone. Finally, the clinical implications for men prescribed ADT for the treatment of advanced prostate cancer are considered.

Publiceringsår

2015

Språk

Engelska

Sidor

464-475

Publikation/Tidskrift/Serie

Urologic Oncology

Volym

33

Issue

11

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Urology and Nephrology

Status

Published

Forskningsgrupp

  • Cardiovascular Research - Immunity and Atherosclerosis

ISBN/ISSN/Övrigt

  • ISSN: 1873-2496